CA3168100A1 - Deoptimized sars-cov-2 and methods and uses thereof - Google Patents

Deoptimized sars-cov-2 and methods and uses thereof

Info

Publication number
CA3168100A1
CA3168100A1 CA3168100A CA3168100A CA3168100A1 CA 3168100 A1 CA3168100 A1 CA 3168100A1 CA 3168100 A CA3168100 A CA 3168100A CA 3168100 A CA3168100 A CA 3168100A CA 3168100 A1 CA3168100 A1 CA 3168100A1
Authority
CA
Canada
Prior art keywords
cov
sars
coronavirus
polynucleotide
various embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168100A
Other languages
English (en)
French (fr)
Inventor
Steffen Mueller
John Robert Coleman
Ying Wang
Chen Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Codagenix Inc
Original Assignee
Serum Institute of India Pvt Ltd
Codagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd, Codagenix Inc filed Critical Serum Institute of India Pvt Ltd
Publication of CA3168100A1 publication Critical patent/CA3168100A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3168100A 2020-01-28 2021-01-27 Deoptimized sars-cov-2 and methods and uses thereof Pending CA3168100A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US62/966,750 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US63/048,942 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US63/079,337 2020-09-16
US202063079853P 2020-09-17 2020-09-17
US63/079,853 2020-09-17
PCT/US2021/015246 WO2021154828A1 (en) 2020-01-28 2021-01-27 DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Publications (1)

Publication Number Publication Date
CA3168100A1 true CA3168100A1 (en) 2021-08-05

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168100A Pending CA3168100A1 (en) 2020-01-28 2021-01-27 Deoptimized sars-cov-2 and methods and uses thereof

Country Status (17)

Country Link
US (1) US20230117167A1 (https=)
EP (1) EP4096712A4 (https=)
JP (1) JP2023519640A (https=)
KR (1) KR20220132588A (https=)
CN (1) CN115427073A (https=)
AU (1) AU2021213121A1 (https=)
BR (1) BR112022014700A2 (https=)
CA (1) CA3168100A1 (https=)
CL (1) CL2022002030A1 (https=)
CO (1) CO2022010743A2 (https=)
IL (1) IL295112A (https=)
MX (1) MX2022009099A (https=)
PE (1) PE20230166A1 (https=)
PH (1) PH12022551788A1 (https=)
SA (1) SA522433428B1 (https=)
TW (1) TW202144570A (https=)
WO (1) WO2021154828A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
CN115297892A (zh) * 2020-02-07 2022-11-04 达冕生物有限公司 抗新型冠状病毒感染的mRNA疫苗的组合物和方法
WO2021177773A2 (ko) * 2020-03-06 2021-09-10 (주)지노믹트리 Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법
US12558415B2 (en) * 2020-04-14 2026-02-24 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
WO2022011428A1 (en) * 2020-07-16 2022-01-20 Griffith University Live-attenuated virus vaccine
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
WO2023018831A2 (en) 2021-08-11 2023-02-16 RNAimmune, Inc. Composition and methods of mrna vaccines against novel coronavirus infection
WO2023037387A2 (en) 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
AU2022435931A1 (en) * 2022-01-20 2024-07-18 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2023186946A1 (en) * 2022-03-28 2023-10-05 Universität Bern One-to-stop attenuated sars-cov-2 virus
EP4331602A1 (en) * 2022-09-05 2024-03-06 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
CA3266020A1 (en) 2022-09-05 2024-03-14 Freie Universitat Berlin LIVE ATTENUATED SARS-CoV-2 AND VACCINE MADE FROM IT
KR20250084962A (ko) * 2022-10-12 2025-06-11 유니버시태트 베른 원-투-스톱 약독화된 SARS-CoV-2 바이러스를 사용한 치료
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
US12280104B2 (en) 2022-11-01 2025-04-22 RNAimmune, Inc. Composition and methods for MRNA vaccines against novel omicron coronavirus infections
WO2025081050A1 (en) * 2023-10-13 2025-04-17 Duke University Coronavirus stem helix and fusion peptide nanoparticle vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
DK3312272T3 (da) * 2004-10-08 2019-12-02 Us Gov Health & Human Services Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
EP4368202A3 (en) * 2007-03-30 2024-08-21 The Research Foundation for The State University of New York Attenuated viruses useful for vaccines
TW201125984A (en) * 2009-10-09 2011-08-01 Univ New York State Res Found Attenuated influenza viruses and vaccines
US10953083B2 (en) * 2015-12-11 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
MX2019011599A (es) * 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
US20200299651A1 (en) * 2017-10-16 2020-09-24 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes

Also Published As

Publication number Publication date
AU2021213121A1 (en) 2022-08-18
KR20220132588A (ko) 2022-09-30
US20230117167A1 (en) 2023-04-20
SA522433428B1 (ar) 2024-10-08
CN115427073A (zh) 2022-12-02
PE20230166A1 (es) 2023-02-01
EP4096712A1 (en) 2022-12-07
WO2021154828A1 (en) 2021-08-05
EP4096712A4 (en) 2024-05-08
IL295112A (en) 2022-09-01
JP2023519640A (ja) 2023-05-11
PH12022551788A1 (en) 2024-02-26
CL2022002030A1 (es) 2023-03-10
BR112022014700A2 (pt) 2022-10-11
TW202144570A (zh) 2021-12-01
MX2022009099A (es) 2022-10-20
CO2022010743A2 (es) 2022-08-30

Similar Documents

Publication Publication Date Title
US20230117167A1 (en) DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF
US20230338506A1 (en) Respiratory virus immunizing compositions
EP3394085B1 (en) Feline calicivirus vaccine
WO2016026264A1 (zh) 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
US11065328B2 (en) Vaccine against infectious bronchitis virus
EP2618841B1 (en) Bvdv vaccine
US20210401983A1 (en) Arthrogenic alphavirus vaccine
SK18232000A3 (sk) Živá vakcína, pestivírus, bvdv pestivírus, nukleová kyselina, bvdv nukleová kyselina, spôsob oslabenia pestivírusov, spôsob výroby vakcíny, farmaceutický prostriedok s jej obsahom a jej použitie
US20240299533A1 (en) Deoptimized sars-cov-2 variants and methods and uses thereof
EA011878B1 (ru) Респираторно-синцитиальный вирус с перекрестно компенсированным геномным дефицитом
MX2015000789A (es) Composiciones de virus de la gripe bovina.
WO2018146257A1 (en) Hepatitis e virus vaccine
WO2005016247A2 (en) Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars
JP2018523708A (ja) マイコプラズマ・ボビス組成物
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
US20240400620A1 (en) Compositions Containing Coronavirus Proteins and Epitopes
US20250312441A1 (en) Immunogenic compositions for herpes simplex virus proteins
Enterovirus Jorge CG Blanco1✉, Fatoumata YD Sylla1, Sandra Granados1, Alessio Noghero2, Marina S. Boukhvalova1 & Adriana E. Kajon2
US20230285542A1 (en) Coronavirus Vaccine
HK40095771A (zh) 预防突变株的新型冠状病毒mRNA疫苗
BR112018074277B1 (pt) Proteína do capsídeo mutada de vírus chikungunya (chikv) isolada, purificada, sintética ou recombinante, poliproteína estrutural nascente de chikv isolada, purificada, sintética ou recombinante, chikv recombinante, alfavírus quimérico, usos dos mesmos, bem como vacina e método de preparo da mesma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260310